After graduating from Cornell University in 1987 and receiving her MD from the Yale University School of Medicine in1991, Dr. Richard completed neurology residency at the University of Rochester in 1995, followed by the NIH-funded fellowship training in Movement Disorders and Experimental Therapeutics in 1997. She joined the faculty of the University of Rochester in 1997 and has been an integral part of the Department of Neurology's missions in clinical care, research and education. The recipient of the Senior Faculty Award in 2013, Dr. Richard is a Professor of Neurology and Psychiatry.

Dr. Richard provides neurological care for patients with Parkinson's disease and related conditions and her research program focuses on the psychiatric aspects of these illnesses. She is the author of numerous scientific articles, editorials and book chapters and has been the recipient of career development awards and research grants, including one from NIH to lead a multi-center clinical trial evaluating the treatment of depression in PD. Dr. Richard serves as a reviewer for scientific journals and served as a member of the NIH Adult Psychopathology and Disorders of Aging Study as well as chair for several research grant review committee meetings for the Michael J. Fox Foundation (MJFF) for Parkinson's disease Research. She served as the Senior Medical Advisor for MJFF, is a member of the scientific advisory board and was the recipient of the 2011 Langtson Award for her valued contributions to the foundation. She has given lectures and chaired workshops and symposia at national meetings including the American Academy of Neurology and The World Parkinson Congress. Dr. Richard's efforts have brought new clinical and research attention to the previously overlooked area of mood disturbances in PD.
Dr. Richard is dedicated to medical education at every level of training and serves as a member of the medical student clerkship grading committee, a faculty preceptor for the neurology resident longitudinal care clinic, director of the psychiatry resident neurology lecture series and director of the movement disorders fellowship program.

Faculty Appointments

Professor (Part-Time) - Department of Neurology, Movement Disorders (SMD)

Professor (Part-Time) - Department of Psychiatry (SMD) - Joint

Credentials

Residency & Fellowship

Fellowship, Movement Disorders, University of Rochester Medical Center. 1995 - 1997

Residency, Neurology, University of Rochester Medical Center. 1992 - 1995

Internship, Internal Medicine, University of Rochester Medical Center. 1991 - 1992

Education

MD | Yale University School of Medicine. 1991

Awards

Fellow of the American Academy of Neurology. 2017

Department of Neurology Senior Faculty Award. 2013

Langston Award, Michael J. Fox Foundation. 2011

Elected Member, American Neurological Association. 2005

Rock Sleyster Scholar (Psychiatry). 1990

Presidential Scholar, Cornell University. 1987

Cornell University, ALS Honor Society, President. 1987

Cornell University, First Place, Public Speaking Competition. 1987

Phi Kappa Phi Honor Society. 1985

Research

Dr. Richard's clinical research is aimed at understanding the pathophysiology of and developing effective treatments (medical and surgical) through clinical trials for neurological and psychiatric aspects of movement disorders, with a particular emphasis on depression in Parkinson's disease.

Publications

Journal Articles

Reply: "An Insight into Long-Term Outcomes in a Parkinson's Disease Minor Phenomena Cohort".

Schneider RB, Weber MT, Elmer AT, Lizarraga KJ, Richard IH, McDermott MP

Movement disorders clinical practice.. 2025 October 12 (10):1688-1689. Epub 07/14/2025.

Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.

Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M

NPJ digital medicine.. 2025 June 168 (1):365. Epub 06/16/2025.

Long-Term Outcomes in a Parkinson's Disease Minor Phenomena Cohort.

Schneider RB, Singh A, Weber MT, Elmer AT, Amodeo K, Lizarraga KJ, Richard IH, McDermott MP

Movement disorders clinical practice.. 2025 May 7 Epub 05/07/2025.

Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.

Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, Simuni T, Postuma RB, Pavese N, Stocchi F, Brockmann K, Smigorski K, Gerbaldo V, Fontoura P, Doody R, Kerchner GA, Brundin P, Marek K, Bonni A, Nikolcheva T

Nature medicine.. 2024 December 30 (12):3669-3675. Epub 10/08/2024.

Long-Term Dementia Risk in Parkinson Disease.

Gallagher J, Gochanour C, Caspell-Garcia C, Dobkin RD, Aarsland D, Alcalay RN, Barrett MJ, Chahine L, Chen-Plotkin AS, Coffey CS, Dahodwala N, Eberling JL, Espay AJ, Leverenz JB, Litvan I, Mamikonyan E, Morley J, Richard IH, Rosenthal L, Siderowf AD, Simuni T, York MK, Willis AW, Xie SX, Weintraub D,

Neurology.. 2024 September 10103 (5):e209699. Epub 08/07/2024.

Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.

Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Brockmann K, Svoboda H, Trundell D, Monnet A, Doody R, Fontoura P, Kerchner GA, Brundin P, Nikolcheva T, Bonni A

Nature medicine.. 2024 April 30 (4):1096-1103. Epub 04/15/2024.

Editorial: Hospitalization and Parkinson's disease: safety, quality and outcomes.

Azmi H, Walter BL, Brooks A, Richard IH, Amodeo K, Okun MS

Frontiers in aging neuroscience.. 2024 16 :1398947. Epub 04/04/2024.

Association of Postoperative Delirium and Parkinson Disease After Common United States Surgical Procedures.

Dham B, Richard I, Schneider EB, George BP

The Journal of surgical research.. 2023 November 291 :711-719. Epub 08/09/2023.

Complications and outcomes of hospitalizations for patients with and without Parkinson disease.

George BP, Barbosa WA, Sethi A, Richard IH

Frontiers in aging neuroscience.. 2023 15 :1276731. Epub 12/15/2023.

Effect of best practice advisory on the administration of contraindicated medications to hospitalized patients with Parkinson's disease and related disorders.

Chunga N, Amodeo K, Braun M, Valdovinos BY, Richard IH

Frontiers in aging neuroscience.. 2023 15 :1276761. Epub 12/18/2023.

Standardizing default electronic health record tools to improve safety for hospitalized patients with Parkinson's disease.

Wu AD, Walter BL, Brooks A, Buetow E, Amodeo K, Richard I, Mundth K, Azmi H

Frontiers in aging neuroscience.. 2023 15 :1278322. Epub 01/18/2024.

Trial of Prasinezumab in Early-Stage Parkinson's Disease.

Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A, ,

The New England journal of medicine.. 2022 August 4387 (5):421-432. Epub 1900 01 01.

Change in the Parkinson Anxiety Scale correlates with change in other clinical measures of anxiety over time.

Schneider RB, Auinger P, Tarolli CG, Iourinets J, Gil Díaz MC, Richard IH

Clinical parkinsonism & related disorders.. 2022 6 :100126. Epub 12/13/2021.

The Importance of Cross-Disciplinary Research: A Commentary on "Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease".

Schneider RB, Richard IH

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2021 September 29 (9):969-971. Epub 01/19/2021.

Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting.

Goldman JG, Boeve BF, Armstrong MJ, Galasko DR, Galvin JE, Irwin DJ, Leverenz JB, Marder K, Abler V, Biglan K, Irizarry MC, Keller B, Lai R, Munsie L, Belleville M, Chaney O, Richard I, Taylor A, Graham T

Alzheimer's research & therapy.. 2021 July 813 (1):124. Epub 07/08/2021.

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.

Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A, ,

Frontiers in neurology. 2021 12 :705407. Epub 10/01/2021.

Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression.

Jackson H, Anzures-Cabrera J, Taylor KI, Pagano G, ,

Frontiers in neuroscience.. 2021 15 :765765. Epub 12/13/2021.

A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.

Schneider RB, Auinger P, Tarolli CG, Iourinets J, Gil-Díaz MC, Richard IH

Parkinsonism & related disorders.. 2020 December 81 :69-74. Epub 10/13/2020.

Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease.

Pontone GM, Dissanayaka N, Apostolova L, Brown RG, Dobkin R, Dujardin K, Friedman JH, Leentjens AFG, Lenze EJ, Marsh L, Mari L, Monchi O, Richard IH, Schrag A, Strafella AP, Vernaleo B, Weintraub D, Mari Z

NPJ Parkinson's disease.. 2020 June 26 (1):10. Epub 06/02/2020.

Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial.

Annals of internal medicine.. 2020 May 5172 (9):591-598. Epub 03/31/2020.

Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.

Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, Alcalay RN, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Nudelman K, Tosun-Turgut D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Bressman S, Marek K,

Movement disorders : official journal of the Movement Disorder Society.. 2020 May 35 (5):833-844. Epub 02/19/2020.

Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease.

Weintraub D, Caspell-Garcia C, Simuni T, Cho HR, Coffey CS, Aarsland D, Alcalay RN, Barrett MJ, Chahine LM, Eberling J, Espay AJ, Hamilton J, Hawkins KA, Leverenz J, Litvan I, Richard I, Rosenthal LS, Siderowf A, York M

Annals of clinical and translational neurology.. 2020 April 7 (4):449-461. Epub 04/13/2020.

Erratum: Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease.

NPJ Parkinson's disease.. 2020 6 :10. Epub 06/02/2020.

Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings.

Peterson B, Armstrong M, Galasko D, Galvin JE, Goldman J, Irwin D, Paulson H, Kaufer D, Leverenz J, Lunde A, McKeith IG, Siderowf A, Taylor A, Amodeo K, Barrett M, Domoto-Reilly K, Duda J, Gomperts S, Graff-Radford N, Holden S, Honig L, Huddleston D, Lippa C, Litvan I, Manning C, Marder K, Moussa C, Onyike C, Pagan F, Pantelyat A, Pelak V, Poston K, Quinn J, Richard I, Rosenthal LS, Sabbagh M, Scharre D, Sha S, Shill H, Torres-Yaghi Y, Christie T, Graham T, Richards I, Koehler M, Boeve B

Alzheimer's research & therapy.. 2019 March 1311 (1):23. Epub 03/13/2019.

Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease.

Pontone GM, Dissanayka N, Apostolova L, Brown RG, Dobkin R, Dujardin K, Friedman JH, Leentjens AFG, Lenze EJ, Marsh L, Mari L, Monchi O, Richard IH, Schrag A, Strafella AP, Vernaleo B, Weintraub D, Mari Z

NPJ Parkinson's disease.. 2019 5 :30. Epub 12/11/2019.

Cognition among individuals along a spectrum of increased risk for Parkinson's disease.

Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D

PloS one.. 2018 13 (8):e0201964. Epub 08/20/2018.

Parkinson's disease psychosis: presentation, diagnosis and management.

Schneider RB, Iourinets J, Richard IH

Neurodegenerative disease management.. 2017 December 7 (6):365-376. Epub 11/21/2017.

National randomized controlled trial of virtual house calls for Parkinson disease.

Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W,

Neurology.. 2017 September 1289 (11):1152-1161. Epub 08/16/2017.

Virtual visits for Parkinson disease: A multicenter noncontrolled cohort.

Korn RE, Shukla AW, Katz M, Keenan HT, Goldenthal S, Auinger P, Zhu W, Dodge M, Rizer K, Achey MA, Byrd E, Barbano R, Richard I, Andrzejewski KL, Schwarz HB, Dorsey ER, Biglan KM, Kang G, Kanchana S, Rodriguez R, Tanner CM, Galifianakis NB

Neurology. Clinical practice.. 2017 August 7 (4):283-295. Epub 1900 01 01.

Long-term follow-up of a randomized AAV2- gene therapy trial for Parkinson's disease.

Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Sapan CV, Eidelberg D, During MJ, Kaplitt MG, Feigin A

JCI insight.. 2017 April 62 (7):e90133. Epub 04/06/2017.

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease.

Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D

PloS one.. 2017 12 (5):e0175674. Epub 05/17/2017.

National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers.

Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W

Telemedicine journal and e-health : the official journal of the American Telemedicine Association.. 2016 July 22 (7):590-8. Epub 02/17/2016.

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.

Simuni T, Long JD, Caspell-Garcia C, Coffey CS, Lasch S, Tanner CM, Jennings D, Kieburtz KD, Marek K,

Annals of clinical and translational neurology.. 2016 July 3 (7):482-94. Epub 05/17/2016.

Modeling anxiety in Parkinson's disease.

Broen MP, Köhler S, Moonen AJ, Kuijf ML, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez-Martin P, Leentjens AF

Movement disorders : official journal of the Movement Disorder Society.. 2016 March 31 (3):310-6. Epub 12/21/2015.

Trajectories of recovery in depressed Parkinson's disease patients treated with paroxetine or venlafaxine.

Broen MP, Leentjens AF, Köhler S, Kuijf ML, McDonald WM, Richard IH

Parkinsonism & related disorders.. 2016 February 23 :80-5. Epub 12/21/2015.

Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings.

Chahine LM, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D,

Movement disorders : official journal of the Movement Disorder Society.. 2016 January 31 (1):86-94. Epub 08/21/2015.

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA,

Movement disorders : official journal of the Movement Disorder Society.. 2015 June 30 (7):919-27. Epub 03/04/2015.

Factor analysis of the Hamilton Depression Rating Scale in Parkinson's disease.

Broen MP, Moonen AJ, Kuijf ML, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez-Martin P, Leentjens AF

Parkinsonism & related disorders.. 2015 February 21 (2):142-6. Epub 11/29/2014.

Feasibility of Virtual Research Visits in Fox Trial Finder.

Dorsey ER, Wagner JD, Bull MT, Rizzieri A, Grischkan J, Achey MA, Sherer T, Chowdhury S, Meunier C, Cappelletti L, Rocker C, Richard IH, Schwarz H, Kang G, Ahmad SH, Biemiller RA, Biglan KM

Journal of Parkinson's disease.. 2015 5 (3):505-15. Epub 1900 01 01.

Anxiety has specific syndromal profiles in Parkinson disease: a data-driven approach.

Starkstein SE, Dragovic M, Dujardin K, Marsh L, Martinez-Martin P, Pontone GM, Richard IH, Weintraub D, Leentjens AF

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2014 December 22 (12):1410-7. Epub 11/05/2013.

Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease.

Moonen AJ, Wijers A, Leentjens AF, Christine CW, Factor SA, Juncos J, Lyness JM, Marsh L, Panisset M, Pfeiffer R, Rottenberg D, Serrano Ramos C, Shulman L, Singer C, Slevin J, McDonald W, Auinger P, Richard IH

Parkinsonism & related disorders.. 2014 June 20 (6):644-6. Epub 03/18/2014.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K

JAMA neurology.. 2014 May 71 (5):543-52. Epub 1900 01 01.

Managing depression in Parkinson's patients: risk factors and clinical pearls.

Biemiller R, Richard IH

Neurodegenerative disease management.. 2014 4 (4):329-36. Epub 1900 01 01.

Modeling depression in Parkinson disease: disease-specific and nonspecific risk factors.

Leentjens AF, Moonen AJ, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Köhler S

Neurology.. 2013 September 1781 (12):1036-43. Epub 08/14/2013.

Rasch analysis of anxiety scales in Parkinson's disease.

Forjaz MJ, Martinez-Martin P, Dujardin K, Marsh L, Richard IH, Starkstein SE, Leentjens AF

Journal of psychosomatic research.. 2013 May 74 (5):414-9. Epub 03/19/2013.

Anxiety and motor fluctuations in Parkinson's disease: a cross-sectional observational study.

Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE

Parkinsonism & related disorders.. 2012 December 18 (10):1084-8. Epub 07/06/2012.

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W,

Neurology.. 2012 April 1778 (16):1229-36. Epub 04/11/2012.

Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study.

Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, Stern MB, Marek K,

Movement disorders : official journal of the Movement Disorder Society.. 2012 March 27 (3):406-12. Epub 01/11/2012.

A randomized pilot trial of estrogen replacement therapy in post-menopausal women with Parkinson's disease.

Parkinsonism & related disorders.. 2011 December 17 (10):757-60. Epub 08/06/2011.

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A

The Lancet. Neurology.. 2011 April 10 (4):309-19. Epub 1900 01 01.

Symptomatology and markers of anxiety disorders in Parkinson's disease: a cross-sectional study.

Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE

Movement disorders : official journal of the Movement Disorder Society.. 2011 February 1526 (3):484-92. Epub 02/10/2011.

Anxiety rating scales in Parkinson's disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale.

Leentjens AF, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez-Martin P

Movement disorders : official journal of the Movement Disorder Society.. 2011 February 1526 (3):407-15. Epub 03/07/2011.

Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Tröster AI, Uc EY

Movement disorders : official journal of the Movement Disorder Society.. 2010 November 1525 (15):2501-7. Epub 1900 01 01.

Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations.

Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, Goetz CG

Movement disorders : official journal of the Movement Disorder Society.. 2008 October 3023 (14):2004-14. Epub 1900 01 01.

Anxiety rating scales in Parkinson's disease: critique and recommendations.

Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, Goetz CG

Movement disorders : official journal of the Movement Disorder Society.. 2008 October 3023 (14):2015-25. Epub 1900 01 01.

Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes.

Palumbo DR, Sallee FR, Pelham WE, Bukstein OG, Daviss WB, McDermott MP

Journal of the American Academy of Child and Adolescent Psychiatry.. 2008 February 47 (2):180-188. Epub 1900 01 01.

Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis.

Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE, Palumbo D, Harris P, Sallee FR

Journal of the American Academy of Child and Adolescent Psychiatry.. 2008 February 47 (2):189-198. Epub 1900 01 01.

The patients' perspective: Results of a survey assessing knowledge about and attitudes toward depression in PD.

Richard IH, LaDonna KA, Hartman R, Podgorski C, Kurlan R,

Neuropsychiatric disease and treatment.. 2007 December 3 (6):903-6. Epub 1900 01 01.

Levodopa responsiveness in disorders with parkinsonism: a review of the literature.

Constantinescu R, Richard I, Kurlan R

Movement disorders : official journal of the Movement Disorder Society.. 2007 November 1522 (15):2141-8; quiz 2295. Epub 1900 01 01.

Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.

Biglan KM, Holloway RG, McDermott MP, Richard IH,

Neurology.. 2007 July 1069 (2):187-95. Epub 1900 01 01.

Depression and apathy in Parkinson's disease.

Richard IH

Current neurology and neuroscience reports.. 2007 July 7 (4):295-301. Epub 1900 01 01.

Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.

Kurlan R, Cummings J, Raman R, Thal L,

Neurology.. 2007 April 2468 (17):1356-63. Epub 1900 01 01.

The patient's perspective: Results of a survey assessing knowledge about and attitudes toward depression in PD

Richard, I.H.; LaDonna, K.; Hartman, R.; Podgorski, C.; Kurlan, R. and the SAD-PD Study Group.

Neuropsychiatric Disease and Treatment. 2007; 3(6): 903-906.

Medication tolerance and augmentation in restless legs syndrome: the need for drug class rotation.

Kurlan R, Richard IH, Deeley C

Journal of general internal medicine.. 2006 December 21 (12):C1-4. Epub 1900 01 01.

The under-recognition of depression in Parkinson's disease.

Richard IH, Kurlan R

Neuropsychiatric disease and treatment.. 2006 September 2 (3):349-53. Epub 1900 01 01.

Apathy does not equal depression in Parkinson disease: why we should care.

Richard IH

Neurology.. 2006 July 1167 (1):10-1. Epub 1900 01 01.

Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group.

Marsh L, McDonald WM, Cummings J, Ravina B,

Movement disorders : official journal of the Movement Disorder Society.. 2006 February 21 (2):148-58. Epub 1900 01 01.

The under-recognition of depression in Parkinson's disease

Richard, I.H.; Kurlan, R.

Neuropsychiatric Disease and Treatment. 2006; 2(3): 349-353.

Mood fluctuations in Parkinson's disease: a pilot study comparing the effects of intravenous and oral levodopa administration.

Richard IH, Frank S, Ladonna KA, Wang H, McDermott MP, Kurlan R

Neuropsychiatric disease and treatment.. 2005 September 1 (3):261-8. Epub 1900 01 01.

Anxiety disorders in Parkinson's disease.

Richard IH

Advances in neurology.. 2005 96 :42-55. Epub 1900 01 01.

Levodopa and the progression of Parkinson's disease.

Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K,

The New England journal of medicine.. 2004 December 9351 (24):2498-508. Epub 1900 01 01.

The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations.

Richard IH, Frank S, McDermott MP, Wang H, Justus AW, Ladonna KA, Kurlan R

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.. 2004 December 17 (4):201-7. Epub 1900 01 01.

Can "blue" genes affect mood and movement?

Richard IH, McDonald WM

Neurology.. 2004 August 2463 (4):610-1. Epub 1900 01 01.

A reality test: How well do we understand psychosis in Parkinson's disease?

Ismail MS, Richard IH

The Journal of neuropsychiatry and clinical neurosciences.. 2004 16 (1):8-18. Epub 1900 01 01.

Prevalence, etiology, and treatment of depression in Parkinson's disease.

McDonald WM, Richard IH, DeLong MR

Biological psychiatry.. 2003 August 154 (3):363-75. Epub 1900 01 01.

Longitudinal outcome of Parkinson's disease patients with psychosis.

Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R,

Neurology.. 2003 June 1060 (11):1756-61. Epub 1900 01 01.

Evaluation of the long-duration benefit from levodopa: results form the ELLDOPA (Earlier vs. later LevoDOPA) Study

Fahn, S.; Parkinson Study Group.

Movement Disorders. 2003; 18(9): 1085-1086.

Does levodopa slow or hasten the rate of progression of Parkinson disease? The results of the ELLDOPA trial

Parkinson Study Group.

Neurology. 2003; 60: A80-A81.

Beta-CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-CIT study: Long-term imaging

Marek, K.L.; Seibyl, J.; Parkinson Study Group.

Neurology. 2003; 160: A293.

Parkinson's disease and dementia with Lewy bodies: one disease or two?

Richard IH, Papka M, Rubio A, Kurlan R

Movement disorders : official journal of the Movement Disorder Society.. 2002 November 17 (6):1161-5. Epub 1900 01 01.

Treatment of ADHD in children with tics: a randomized controlled trial.

Neurology.. 2002 February 2658 (4):527-36. Epub 1900 01 01.

Depressive symptoms in Parkinson's diseases are underrecognized

Richard, I.H.; Justus, A.W.; Caine, E.; Kurlan, R.

Journal of Neuropsychiatry and Clinical Neurosciences. 2002; 14: 108.

Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine.

Richard IH, Justus AW, Greig NH, Marshall F, Kurlan R

Clinical neuropharmacology.. 2002 25 (6):296-9. Epub 1900 01 01.

Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial.

Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K,

Movement disorders : official journal of the Movement Disorder Society.. 2001 January 16 (1):135-9. Epub 1900 01 01.

Rivastigmine-induced worsening of motor function and mood in a patient with Parkinson's disease

Richard, I.H.; Justus, A.W.; Grieg, N.; Marshall, F.; Kurlan, R.

Movement Disorders. 2001; 16(Supplement 1): S32.

Relationship between mood and motor fluctuations in Parkinson's disease.

Richard IH, Justus AW, Kurlan R

The Journal of neuropsychiatry and clinical neurosciences.. 2001 13 (1):35-41. Epub 1900 01 01.

Worsening of motor function in Parkinson's disease: a "typical" response to "atypical" antipsychotic medications.

Richard IH, Nutt J

Neurology.. 2000 September 2655 (6):748-9. Epub 1900 01 01.

Depression in Parkinson's Disease.

Richard IH

Current treatment options in neurology.. 2000 May 2 (3):263-274. Epub 1900 01 01.

Movement disorders in Alzheimer's disease: more rigidity of definitions is needed.

Kurlan R, Richard IH, Papka M, Marshall F

Movement disorders : official journal of the Movement Disorder Society.. 2000 January 15 (1):24-9. Epub 1900 01 01.

Tourette's syndrome: presentation and treatment complexities

Richard, I.H.

Journal Watch Neurology. Comments on and review of Robertson, M.M. Tourette's syndrome, associated conditions and the complexities of treatment. Brain 2000;123:426-462. 2000; 2: 46.

Worsening of motor function in Parkinson's disease: "A-typical" response to "atypical" antipsychotic medications [Editorial].

Richard IH; Nutt J.

Neurology. 2000; 55: 748-749.

Commentary to cognitive and behavioral heterogeneity.

Richard I, Kurlan R

Neurobiology of aging.. 2000 21 (6):863-4; discussion 875-7. Epub 1900 01 01.

Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease.

The New England journal of medicine.. 1999 March 11340 (10):757-63. Epub 1900 01 01.

Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series.

Richard IH, Maughn A, Kurlan R

Movement disorders : official journal of the Movement Disorder Society.. 1999 January 14 (1):155-7. Epub 1900 01 01.

Parkinson's disease: a preliminary study of yohimbine challenge in patients with anxiety.

Richard IH, Szegethy E, Lichter D, Schiffer RB, Kurlan R

Clinical neuropharmacology.. 1999 22 (3):172-5. Epub 1900 01 01.

Non-barbiturate, drug-induced reversible loss of brainstem reflexes.

Richard IH, LaPointe M, Wax P, Risher W

Neurology.. 1998 August 51 (2):639-40. Epub 1900 01 01.

Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group.

Neurology.. 1998 May 50 (5):1366-73. Epub 1900 01 01.

Anxiety and Parkinson's disease

Richard, I.H.; Schiffer, R.B.; Kurlan, R.

Journal of Neuropsychiatry and Clinical Neurosciences. 1998; 8: 383-392.

Low dose clozapine for the treatment of drug-induced psychosis in idiopathic Parkinson's disease: Results of the double-blind, placebo controlled PSYCLOPS trial

Friedman, J.H.; Comella, C.; Factor, S.; Kurlan, R.; Parsa, M.; Pfeiffer, R.; Richard, I.; Parkinson Study Group.

Neurology. 1998; 50(Supplement 4): A70.

A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group.

Richard IH, Kurlan R

Neurology.. 1997 October 49 (4):1168-70. Epub 1900 01 01.

Mood Disorders Secondary to Demyelinating and Movement Disorders.

Meyerson RA, Richard IH, Schiffer RB

Seminars in clinical neuropsychiatry.. 1997 October 2 (4):252-264. Epub 1900 01 01.

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C

Neurology.. 1997 April 48 (4):1070-7. Epub 1900 01 01.

Anxiety and Parkinson's disease.

Richard IH, Schiffer RB, Kurlan R

The Journal of neuropsychiatry and clinical neurosciences.. 1996 8 (4):383-92. Epub 1900 01 01.

Retrospective and concurrent self-report of behavioral inhibition and their relation to adult mental health

Reznick, J.S.; Hegeman, I.M.; et al.

Development and Psychopathology. 1992; 4: 301-321.

Visual stimulation increases technetium-99m-HMPAO distribution in human visual cortex.

Woods SW, Hegeman IM, Zubal IG, Krystal JH, Koster K, Smith EO, Heninger GR, Hoffer PB

Journal of nuclear medicine : official publication, Society of Nuclear Medicine.. 1991 February 32 (2):210-5. Epub 1900 01 01.

Books

Geriatric Rehabilitation: From Bedside to Curbside (2017)

Chapter: Parkinson's Disease

Authors: Beimiller Rachel and Richard IH

Publisher: CRC Press, Taylor and Francis Group, Boca Raton, Florida 2017

Parkinson's Disease: Non-Motor and Non-Dopaminergic Features (2011)

Chapter: Depression in PD

Authors: Voss T and Richard IH

Publisher: Wiley Blackwell, West Sussex, England 2011

Movement Disorders: 100 Instructive Cases (2006)

Authors: Richard, I.H.; Kurlan, R.

Publisher: Taylor and Francis Books, Abington, UK 2006

Secondary Dementias (2006)

Chapter: Cognitive Impairment in Depression

Authors: Richard, I.H.

Publisher: Taylor & Francis, New York 2006

Psychiatric Issues in Parkinson's Disease: A Practical Guide (2006)

Chapter: Management of Advanced Stage Disease

Authors: Richard, I.H.

Publisher: Taylor & Francis, London 2006

Current Clinical Neurology: Psychiatry for Neurologists (2005)

Chapter: An Overview of Depression

Authors: Richard, I.H.; Lyness, J.M.

Publisher: Humana Press, Boston 2005

Drug Induced Movement Disorders, 2nd Edition (2005)

Chapter: Spontaneous Movement Disorders in Psychiatric Patients

Authors: Richard, I.; O'Brien, C.; Kurlan, R.

Publisher: Blackwell Publishers 2005

Parkinson's Disease: Diagnosis and Clinical Management (2002)

Chapter: Anxiety and Panic

Authors: Richard, I.H.; Kurlan, R.

Publisher: Demos, New York 2002

Current Treatment Options in Neurology (2000)

Chapter: Depression in Parkinson's Disease

Authors: Ricahrd, I.H.

Publisher: Unknown 2000

The Neurologist (1998)

Chapter: Acute, Drug-Induced, Life-Threatening Neurological Syndromes

Authors: Richard, I.H.

Publisher: Unknown 1998

Seminars in Clinical Neuropsychiatry (1997)

Chapter: Mood Disorders secondary to Demyelinating and Movement Disorders

Authors: Meyerson, R.A.; Richard, I.H.; Schiffer, R.B.

Publisher: Unknown 1997

Neurobase, 3rd and 4th Edition (1996)

Chapter: Dementia of Huntington's Disease

Authors: Richard, I.H.; Shoulson, I.

Publisher: Arbor Publishing, San Diego, CA 1996

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

Care provider's discussion of any proposed treatment (options, risks, benefits, etc.)

4.8

Likelihood of recommending this care provider to others

4.9

Explanations the care provider gave you about your problem or condition

4.9

Care provider's efforts to include you in decisions about your care

4.9

Concern the care provider showed for your questions or worries

4.9

Patient Comments

5.0

I enjoyed the visit and appreciated the time and effort the doctor allowed for my first exam at UR. Having PD, it is very difficult for me to understand all the areas on impact by the disease and medicine. It's a long journey and I feel very comfortable UoR is the best place for me,

Sep 22, 2025

5.0

Good

Aug 17, 2025

5.0

Dr. Richard was wonderful.

Aug 17, 2025

5.0

Dr Richard listened very carefully to us about my husbands condition. She was very caring and compassionate

Aug 16, 2025

5.0

Everything was explained extremely detailed and clearly.

May 11, 2023